Researchers have determined that a liquid biopsy human papillomavirus DNA test may serve as a useful tool for the diagnosis and surveillance of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC).

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of cancer patients.

Quest Diagnostics said it completed its previously announced acquisition of Haystack Oncology.

China-based, blood cancer early detection and monitoring technology company, SeekIn has released new research on its multi-cancer early detection (MCED) test, OncoSeek.

Global life sciences company Labcorp has introduced a new liquid biopsy test called Labcorp Plasma Focus.

UK circulating tumor cell firm Angle said Wednesday that it has signed an agreement with BioView to develop a liquid biopsy HER2 assay using its cell isolation technology, Parsortix, and BioView's automated microscopy systems and software.

Naveris said Wednesday that Mayo Clinic began a Phase II trial of its circulating tumor DNA blood test, NavDx, to guide treatment for patients with HPV-driven head and neck cancer.

Foundation Medicine said Tuesday that it has expanded an ongoing collaboration with Bristol Myers Squibb to include companion diagnostic development for the pharma firm's investigational tyrosine kinase inhibitor repotrectinib.

Chinese immunodiagnostics market has maintained an overall growth rate of approximately 20% over the past five years, and is expected to reach a market size of CNY 52.4 billion in 2022.

On March 27, 2023, MGI and Fujian Berry Oncology Co., Ltd. signed the strategic cooperation agreement.